Lazertinib (YH25448) is a potent, irreversible, and orally bioavailable third-generation EGFR tyrosine kinase inhibitor with high selectivity for mutant EGFRs. It effectively targets EGFR mutations including L858R/T790M, Del19/T790M, and Del19 with IC50 values of 1.7, 2, and 3.3 nM, respectively, while sparing wild-type EGFR and other ErbB family members. Lazertinib crosses the blood-brain barrier and reduces tumor volume in EGFRT790M mutant NSCLC xenograft models, making it suitable for research in non-small cell lung cancer. Reagent grade, for research purpose.
Usually ships within 24 hours.